TAO Synergies (TAOX) Prepaid Assets (2019 - 2026)
TAO Synergies' (TAOX) quarterly Prepaid Assets came in at $1.4 million in Q2 2026, up 56.2% on a YoY basis from $921349.0 in Q2 2025, and little changed quarter-over-quarter from $1.4 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Prepaid Assets (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Prepaid Assets for 8 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 56.2% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 56.2% YoY), and the FY2025 full-year result was $2.0 million, up 2923.07% from the prior year.
- Prepaid Assets was little changed at $1.4 million in Q2 2026 per TAOX's latest filing, from $1.4 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $2.0 million in Q4 2025 and bottomed at $57677.0 in Q4 2023.
- Historically, Prepaid Assets has averaged $702890.7 across 5 years, with a median of $541808.5 in 2022.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets slumped 92.2% in 2023, then jumped 2923.07% in 2025.
- Over 5 years, Prepaid Assets stood at $739467.0 in 2022, then plunged by 92.2% to $57677.0 in 2023, then gained by 12.06% to $64633.0 in 2024, then surged by 2923.07% to $2.0 million in 2025, then retreated by 26.34% to $1.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.4 million, $1.4 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.86 Mn | 30.86 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Mar 31, 2026 | 1.44 Mn |
| Dec 31, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 921,349.00 |
| Mar 31, 2025 | 484,153.00 |
| Dec 31, 2024 | 64,633.00 |
| Sep 30, 2024 | 211,230.00 |
| Jun 30, 2024 | 411,150.00 |
| Mar 31, 2024 | 560,583.00 |
| Dec 31, 2023 | 57,677.00 |
| Sep 30, 2023 | 238,109.00 |
| Jun 30, 2023 | 385,769.00 |
| Mar 31, 2023 | 586,364.00 |
| Dec 31, 2022 | 739,467.00 |
| Sep 30, 2022 | 395,342.00 |
| Jun 30, 2022 | 523,034.00 |
| Mar 31, 2022 | 720,211.00 |
| Dec 31, 2021 | 879,869.00 |
| Sep 30, 2021 | 1.05 Mn |